IP Library › Granted Patent US 12,564,733
Granted Patent B2
US 12,564,733 · App. 18/454,663 · Granted Mar 3, 2026

Methods for optimizing treatment time and plan quality for radiotherapy

Inventors: Aleksei Privalikhin (Sosnovy Bor, RU); Yevgen Voronenko (Sunnyvale, CA); Peter Demetri Olcott (Los Gatos, CA)
Assignee: RefleXion Medical, Inc.
A61N5/1048A61N5/103A61N2005/1074
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,564,733
App. No.
18/454,663
Filed
Aug 23, 2023
Granted
Mar 3, 2026
Kind
B2
Art Unit
2172
USPC
715/772
Abstract

Described herein is a graphical user interface that receives a user-specified treatment time value and displays the resultant dose distributions to a target region and/or organs-at-risk (OARs). The dose distributions are depicted as dose volume histograms (DVHs). The user-specified treatment time value may be adjusted as desired and the DVHs for the target region and/or OARs may be correspondingly updated. In some variations, the graphical user interface may comprise bounded DVHs for the target region and/or OARs, where bounds of the DVH represent the range of dose variability between a short treatment time (e.g., T min ) and a long treatment time (e.g., T max ). In some variations, the graphical user interface includes a command button that triggers fluence map optimization using the user-specified treatment time.

Claims (53)

1 . A graphical user interface for radiotherapy planning, the graphical user interface comprising:

a bounded dose volume histogram (bDVH) for a target region comprising a lower bound DVH and an upper bound DVH that represent a range of radiation dose values to the target region over a range of treatment delivery times;

a treatment time selector configured to receive user input that specifies a treatment delivery time within the range of treatment times; and

a variable dose volume histogram (DVH) for the target region that represents a radiation dose to the target region that corresponds to the specified treatment delivery time,

wherein the lower bound DVH corresponds to a lower-limit treatment delivery time value and the upper bound DVH corresponds to an upper-limit treatment delivery time value,

wherein the lower-limit treatment delivery time value is a minimum treatment delivery time value, and the upper-limit treatment delivery time value is a maximum treatment delivery time value, and

wherein the minimum treatment delivery time value is determined by

generating a fluence map comprising a set of beamlet values by iteratively adjusting the beamlet values based on a cost function comprising a treatment time penalty function such that the fluence map delivers a prescribed dose to the target region and changes of a cost function value between iterations of the beamlet values is less than a selected threshold, and

calculating an amount of time to deliver the generated fluence map.

2 . A graphical user interface for radiotherapy planning, the graphical user interface comprising:

a bounded dose volume histogram (bDVH) for a target region comprising a lower bound DVH and an upper bound DVH that represent a range of radiation dose values to the target region over a range of treatment delivery times;

a treatment time selector configured to receive user input that specifies a treatment delivery time within the range of treatment times; and

a variable dose volume histogram (DVH) for the target region that represents a radiation dose to the target region that corresponds to the specified treatment delivery time,

wherein the lower bound DVH corresponds to a lower-limit treatment delivery time value and the upper bound DVH corresponds to an upper-limit treatment delivery time value, wherein the lower-limit treatment delivery time value is a minimum treatment delivery time value, and the upper-limit treatment delivery time value is a maximum treatment delivery time value, and

wherein the maximum treatment delivery time value is determined by

generating a fluence map comprising a set of beamlet values by iteratively adjusting the beamlet values based on a cost function comprising an organ-at-risk (OAR) dose penalty function such that the fluence map delivers a prescribed dose to the target region and changes of a mean dose to the OAR between iterations of the beamlet values is less than a selected threshold, and

calculating an amount of time to deliver the generated fluence map.

3 . A graphical user interface for radiotherapy planning, the graphical user interface comprising:

a bounded dose volume histogram (bDVH) for a target region comprising a lower bound DVH and an upper bound DVH that represent a range of radiation dose values to the target region over a range of treatment delivery times;

a treatment time selector configured to receive user input that specifies a treatment delivery time within the range of treatment times;

a variable dose volume histogram (DVH) for the target region that represents a radiation dose to the target region that corresponds to the specified treatment delivery time;

a treatment time axis;

a lower limit indicator on the treatment time axis, wherein the lower-limit indicator is at a minimum treatment time in the range of treatment times;

an upper limit indicator on the treatment time axis, wherein the upper-limit indicator is at a maximum treatment time in the range of treatment times; and

wherein the treatment time selector is located on the treatment time axis between the lower limit indicator and the upper limit indicator, wherein the treatment time indicator is at an initial treatment time for delivering a prescribed dose to the target region.

4 . The graphical user interface of claim 3 , wherein the initial treatment time is calculated by

generating a fluence map comprising a set of radiation beamlet values by iteratively adjusting the beamlet values based on a cost function comprising an OAR penalty function such that the fluence map delivers the prescribed dose to the target region and changes of a cost function value between iterations of the beamlet values is less than a selected threshold; and

calculating an amount of time to deliver the generated fluence map.

5 . The graphical user interface of claim 3 , wherein the minimum treatment time is determined by

generating a fluence map comprising a set of beamlet values by iteratively adjusting the beamlet values based on a cost function comprising a treatment time penalty function such that the fluence map delivers the prescribed dose to the target region and changes of a cost function value between iterations of the beamlet values is less than a selected threshold, and

calculating an amount of time it takes to deliver the generated fluence map.

6 . The graphical user interface of claim 3 , wherein the maximum treatment time is determined by

generating a fluence map comprising a set of beamlet values by iteratively adjusting the beamlet values based on a cost function comprising an organ-at-risk (OAR) dose penalty function such that the fluence map delivers a prescribed dose to the target region and changes of a mean dose to the OAR between iterations of the beamlet values is less than a selected threshold, and

calculating an amount of time to deliver the generated fluence map.

7 . The graphical user interface of claim 3 , wherein the lower bound DVH corresponds to a lower-limit treatment delivery time value and the upper bound DVH corresponds to an upper-limit treatment delivery time value.

8 . The graphical user interface of claim 7 , wherein the lower-limit treatment delivery time value is a minimum treatment delivery time value, and the upper-limit treatment delivery time value is a maximum treatment delivery time value.

9 . The graphical user interface of claim 3 , wherein the bDVH for the target region further comprises shading between the upper bound DVH curve and the lower bound DVH curve.

10 . The graphical user interface of claim 3 , wherein the variable DVH curve for the target region changes between the upper bound DVH curve and the lower bound DVH curve according to the user input to the treatment time selector.

11 . The graphical user interface of claim 3 , wherein the treatment time selector is a graphical slider that is movable between a first limit that corresponds to a low-threshold treatment delivery time value and a second limit that corresponds to a high-threshold treatment delivery time value, and wherein moving the slider to a position between the first and second limits corresponds to selecting the treatment delivery time.

12 . The graphical user interface of claim 3 , wherein the treatment time selector is a graphical dial that is rotatable between a first limit corresponding to a low-threshold treatment delivery time and a second limit corresponding to a high-threshold treatment delivery time, and wherein setting the dial to a position between the first and second limits corresponds to selecting the treatment delivery time.

13 . The graphical user interface of claim 3 , further comprising a second bDVH for a volume of interest (VOI) comprising a second lower bound DVH curve and a second upper bound DVH curve that represent a range of radiation dose values to the VOI over the range of treatment delivery times, and a second variable DVH curve for the VOI that represents a radiation dose to the VOI that corresponds to the specified treatment delivery time.

14 . The graphical user interface of claim 13 , wherein the second bDVH for the VOI further comprises shading between the upper bound DVH curve and the lower bound DVH curve.

15 . The graphical user interface of claim 13 , wherein the second variable DVH curve for the VOI changes between the upper bound DVH curve and the lower bound DVH curve of the second bDVH for the VOI according to the user input to the treatment time selector.

16 . The graphical user interface of claim 13 , wherein the VOI comprises a heart.

17 . The graphical user interface of claim 13 , wherein the VOI comprises a spinal cord.

18 . The graphical user interface of claim 13 , wherein the VOI comprises an esophagus.

19 . The graphical user interface of claim 13 , wherein the VOI comprises an organ-at-risk (OAR).

20 . The graphical user interface of claim 13 , further comprising a third bDVH for a second VOI comprising a third lower bound DVH curve and a third upper bound DVH curve that represent a range of radiation dose values to the second VOI over the range of treatment delivery times, and a third variable DVH curve for the second VOI that represents a radiation dose to the second VOI that corresponds to the specified treatment delivery time.

21 . The graphical user interface of claim 20 , further comprising a DVH-viewer selection menu that includes a graphical selection toggle for each of the first, second and third bDVHs, wherein a user-selection of a first toggle state displays the corresponding bDVH and a second toggle state hides the corresponding bDVH.

22 . The graphical user interface of claim 21 , wherein the first, second and third bDVHs are each depicted with different colors.

23 . The graphical user interface of claim 3 , further comprising a first text field that indicates a mean dose to the target region and a second text field that indicates a maximum dose to the target region for the specified treatment delivery time.

24 . The graphical user interface of claim 3 , further comprising a graphical indicator of the treatment delivery time specified by the treatment time selector.

25 . The graphical user interface of claim 3 , further comprising a command button that is triggers treatment plan optimization with the treatment delivery time specified by the treatment time selector.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2024
From: PRIVALIKHIN, ALEKSEI; VORONENKO, YEVGEN; OLCOTT, PETER DEMETRI
To: REFLEXION MEDICAL, INC.
Reel/Frame 066892/0180 →
Continuity (3)
Continuation PCTUS2022017370 · Feb 22, 2022
Provisional Application 63153256 · Feb 24, 2021
Related Publication 20230390585A1 · Dec 7, 2023
References Cited (152)
US 5647663A · Holmes · 1997 [cited by applicant]
US 6385286B1 · Fitchard et al. · 2002 [cited by applicant]
US 6618467B1 · Ruchala et al. · 2003 [cited by applicant]
US 6714620B2 · Caflisch et al. · 2004 [cited by applicant]
US 8107589B2 · Sakurai et al. · 2012 [cited by applicant]
US 8315357B2 · Zhu et al. · 2012 [cited by applicant]
US 8605857B1 · Renner · 2013 [cited by applicant]
US 9019307B1 · Grimm · 2015 [cited by applicant]
US 10307615B2 · Ollila et al. · 2019 [cited by applicant]
US 10456600B2 · Owens et al. · 2019 [cited by applicant]
US 10674983B2 · Black · 2020 [cited by applicant]
US 10918884B2 · O'Connor et al. · 2021 [cited by applicant]
US 11167153B2 · Bokrantz et al. · 2021 [cited by applicant]
US 11173322B2 · Kuusela et al. · 2021 [cited by applicant]
US 11648418B2 · Owens et al. · 2023 [cited by applicant]
US 12214219B2 · Owens et al. · 2025 [cited by applicant]
US 12303718B2 · Owens et al. · 2025 [cited by applicant]
US 20020137991A1 · Scarantino et al. · 2002 [cited by applicant]
US 20040079899A1 · Ma · 2004 [cited by applicant]
US 20040096033A1 · Seppi et al. · 2004 [cited by applicant]
US 20040122308A1 · Ding · 2004 [cited by applicant]
US 20050111621A1 · Riker et al. · 2005 [cited by applicant]
US 20050207531A1 · Dempsey et al. · 2005 [cited by applicant]
US 20060173294A1 · Ein-Gal · 2006 [cited by applicant]
US 20080226030A1 · Otto · 2008 [cited by applicant]
US 20090117044A1 · Hengerer et al. · 2009 [cited by applicant]
US 20100086183A1 · Vik et al. · 2010 [cited by applicant]
US 20110163238A1 · Teshigawara et al. · 2011 [cited by applicant]
US 20110200170A1 · Nord et al. · 2011 [cited by applicant]
US 20110283235A1 · Kling · 2011 [cited by examiner]
US 20110291015A1 · Mazin · 2011 [cited by applicant]
US 20120250971A1 · Holmes et al. · 2012 [cited by applicant]
US 20120292534A1 · Geneser et al. · 2012 [cited by applicant]
US 20120323599A1 · Bal et al. · 2012 [cited by applicant]
US 20140005464A1 · Bharat et al. · 2014 [cited by applicant]
US 20140252227A1 · Sasai et al. · 2014 [cited by applicant]
US 20140270053A1 · Larson · 2014 [cited by applicant]
US 20140275704A1 · Zhang et al. · 2014 [cited by applicant]
US 20150161338A1 · Scherrer et al. · 2015 [cited by applicant]
US 20150224342A1 · Baltes et al. · 2015 [cited by applicant]
US 20150251017A1 · De Crevoisier · 2015 [cited by examiner]
US 20150360056A1 · Xing et al. · 2015 [cited by applicant]
US 20160074541A1 · Zalutsky et al. · 2016 [cited by applicant]
US 20160140300A1 · Purdie et al. · 2016 [cited by applicant]
US 20160193480A1 · Ribbing et al. · 2016 [cited by applicant]
US 20160361566A1 · Larkin et al. · 2016 [cited by applicant]
US 20160361568A1 · Chappelow et al. · 2016 [cited by applicant]
US 20170014642A1 · An et al. · 2017 [cited by applicant]
US 20170028220A1 · Schulte et al. · 2017 [cited by applicant]
US 20170095678A1 · Oster et al. · 2017 [cited by applicant]
US 20190091487A1 · Pal · 2019 [cited by examiner]
US 20200197729A1 · Owens et al. · 2020 [cited by applicant]
US 20200306559A1 · Kuusela et al. · 2020 [cited by applicant]
US 20210101021A1 · Fredriksson · 2021 [cited by applicant]
US 20210138267A1 · Nord et al. · 2021 [cited by applicant]
US 20220001209A1 · Owens et al. · 2022 [cited by applicant]
US 20220176156A1 · Meijers · 2022 [cited by examiner]
US 20220199221A1 · Khuntia et al. · 2022 [cited by applicant]
US 20250256126A1 · Owens et al. · 2025 [cited by applicant]
CN 101267767A · 2008 [cited by applicant]
CN 101489477A · 2009 [cited by applicant]
CN 101496018A · 2009 [cited by applicant]
CN 102068763A · 2011 [cited by applicant]
CN 102641561A · 2012 [cited by applicant]
CN 103209736A · 2013 [cited by applicant]
CN 103845068A · 2014 [cited by applicant]
CN 104866928A · 2015 [cited by applicant]
CN 104994909A · 2015 [cited by applicant]
EP 2072081A1 · 2009 [cited by applicant]
EP 2904974A1 · 2015 [cited by applicant]
EP 2990078A1 · 2016 [cited by applicant]
EP 3581241A1 · 2019 [cited by applicant]
EP 3264298A1 · 2020 [cited by applicant]
EP 3546023B1 · 2021 [cited by applicant]
JP 2002522128A · 2002 [cited by applicant]
JP 2009160308A · 2009 [cited by applicant]
JP 2009538195A · 2009 [cited by applicant]
JP 2012035072A · 2012 [cited by applicant]
JP 2013059576A · 2013 [cited by applicant]
JP 2014023741A · 2014 [cited by applicant]
JP 2014503315A · 2014 [cited by applicant]
JP 2016055161A · 2016 [cited by applicant]
JP 2016168077A · 2016 [cited by applicant]
WO WO0059576A1 · 2000 [cited by applicant]
WO WO2008013598A2 · 2008 [cited by applicant]
WO WO2008013598A3 · 2008 [cited by applicant]
WO WO2013024380A1 · 2013 [cited by applicant]
WO WO2013054788A1 · 2013 [cited by applicant]
WO WO2013093852A1 · 2013 [cited by applicant]
WO WO2015168431A1 · 2015 [cited by applicant]
WO WO2016001046A1 · 2016 [cited by applicant]
WO WO2017081768A1 · 2017 [cited by applicant]
WO WO2019238602A1 · 2019 [cited by applicant]
WO WO2020177844A1 · 2020 [cited by applicant]
WO WO2020234032A1 · 2020 [cited by applicant]
WO WO2022003060A1 · 2022 [cited by applicant]
WO WO2024182320A1 · 2024 [cited by applicant]
Adaptive Radiation Therapy: ISBN:9781439816356. 2011. CRC Press. X Allen Li (Ed.): 426 pages (cover only); URL: https:// www.google.com/books/edition/Adaptive_Radiation_Therapy/9hEPvAlgPfMC (accessed Aug. 31, 2021). [cited by applicant]
Chen, X. et al. (2012). “Smoothing proximal gradient method for general structured sparse regression,” The Annals of Applied Statistics 6:719-752. [cited by applicant]
Croteau, E. et al. (2016).“PET Metabolic Biomarkers for Cancer,” Biomark Cancer. 8(Suppl 2):61-69. [cited by applicant]
Extended European Search Report mailed on Oct. 15, 2019, for European Application No. 17 764 132.1, filed on Mar. 9, 2017, 4 pages. [cited by applicant]
Extended European Search Report mailed on Jun. 14, 2021, for EP Application No. 18 821 003.3, filed on Jun. 22, 2018, 5 pages. [cited by applicant]
Extended European Search Report mailed on Mar. 15, 2021, for EP Application No. 18 837 615.6, filed on Jul. 26, 2018, 8 pages. [cited by applicant]
Final Office Action mailed on May 18, 2022, for U.S. Appl. No. 16/016,272, filed Jun. 22, 2018, 31 pages. [cited by applicant]
Final Office Action mailed on Jul. 14, 2021, for U.S. Appl. No. 16/582,308, filed Sep. 25, 2019, 8 pages. [cited by applicant]
Final Office Action mailed on Sep. 15, 2022, for U.S. Appl. No. 16/582,308, filed Sep. 25, 2019, 10 pages. [cited by applicant]
Fredriksson (2013). “Robust optimization of radiation therapy accounting for geometric uncertainty,” KTH Engin. Sciences, pp. 8-14. [cited by applicant]
Hoeben, B.A.W. et al. (2013). “Molecular PET imaging for biology-guided adaptive radiotherapy of head and neck cancer,” Acta Oncologica 52:1257-1271. [cited by applicant]
International Search Report mailed on Jun. 27, 2017, for PCT Patent Application No. PCT/US2017/021647, filed on Mar. 9, 2017, 3 pages. [cited by applicant]
International Search Report mailed on Nov. 16, 2018, for PCT Application No. PCT/US2018/039104, filed on Jun. 22, 2018, 4 pages. [cited by applicant]
International Search Report mailed on Oct. 3, 2018, for PCT Application No. PCT/US2018/043954, filed on Jul. 26, 2018, 3 pages. [cited by applicant]
International Search Report mailed on May 24, 2022, for PCT Patent Application No. PCT/US2022/017370, filed on Feb. 22, 2022, 3 pages. [cited by applicant]
Kim et al. “18F-FDG PET/CT of Advanced Gastric Carcinoma and Association of H ER2 Expression with Standardized Uptake Value.” Asia Oceania J Nucl Med Biol, 2014; 2(1): 12-18. [cited by applicant]
Kong et al. “Effect of Midtreatment PET/CT-Adapted Radiation Therapy with Concurrent Chemotherapy in Patients with Locally Advanced Non-Small-Cell Lung Cancer.” JAMA Oncol. Oct. 2017; 3(10): 1358-1365. Published online … [cited by applicant]
Non-Final Office Action mailed on Jun. 26, 2020, for U.S. Appl. No. 16/122,735, filed Sep. 5, 2018, 16 pages. [cited by applicant]
Non-Final Office Action mailed on Sep. 21, 2021, for U.S. Appl. No. 16/016,272, filed Jun. 22, 2018, 34 pages. [cited by applicant]
Non-Final Office Action mailed on Feb. 11, 2021, for U.S. Appl. No. 16/582,308, filed Sep. 25, 2019, 9 pages. [cited by applicant]
Non-Final Office Action mailed on Jun. 8, 2022, for U.S. Appl. No. 16/582,308, filed Sep. 25, 2019, 9 pages. [cited by applicant]
Non-Final Office Action mailed on Nov. 21, 2022, for U.S. Appl. No. 16/016,272, filed Jun. 22, 2018, 27 pages. [cited by applicant]
Non-Final Office Action mailed on Jun. 29, 2023, for U.S. Appl. No. 17/479,873, filed Sep. 20, 2021, 10 pages. [cited by applicant]
Notice of Allowance mailed on Jul. 25, 2019, for U.S. Appl. No. 16/046,746, filed Jul. 26, 2018, 8 pages. [cited by applicant]
Notice of Allowance mailed on Aug. 15, 2019, for U.S. Appl. No. 16/046,746, filed Jul. 26, 2018, 7 pages. [cited by applicant]
Notice of Allowance mailed on Dec. 11, 2020, for U.S. Appl. No. 16/122,735, filed Sep. 5, 2018, 10 pages. [cited by applicant]
Notice of Allowance mailed on Mar. 9, 2023, for U.S. Appl. No. 16/016,272, filed Jun. 22, 2018, 8 pages. [cited by applicant]
Thorek, D. “Positron lymphography: multimodal, high-resolution, dynamic mapping and resection of lymph nodes after X intradermal injection of 18F-FDG.” J Nucl Med. Sep. 2012;53(9):1438-45. [cited by applicant]
Thorwarth, D. et al. (2010). “Physical radiotherapy treatment planning based on functional PET/CT data,” Radiotherapy Oncology, pp. 317-324. [cited by applicant]
Tuncel, N. “Adaptive radiotherapy from past to future frontiers.” International Journal of Radiology & Radiation Therapy 2021; 8(2):81-84. [cited by applicant]
Written Opinion of the International Searching Authority mailed on Jun. 27, 2017, for PCT Patent Application No. PCT/US2017/021647, filed on Mar. 9, 2017, 5 pages. [cited by applicant]
Written Opinion of the International Searching Authority mailed on Nov. 16, 2018, for PCT Application No. PCT/US2018/039104, filed on Jun. 22, 2018, 6 pages. [cited by applicant]
Written Opinion of the International Searching Authority mailed on Oct. 3, 2018, for PCT Application No. PCT/US2018/043954, filed on Jul. 26, 2018, 5 pages. [cited by applicant]
Written Opinion of the International Searching Authority mailed on May 24, 2022, for PCT Patent Application No. PCT/US2022/017370, filed on Feb. 22, 2022, 9 pages. [cited by applicant]
Yan, D. et al. (1997). “Adaptive radiation therapy,” [cited by applicant]
Zhang, H. et al. (2002). Progress in the Physics of Tumor Radiation Therapy, Beijing Medical University, China Union Medical University Joint Press, p. 164 (with English translation). [cited by applicant]
Zhao, H. et al. (2015). Practical Imaging Diagnosis, University Press, Aug. 2015, p. 167 (with English translation). [cited by applicant]
Extended European Search Report mailed on May 31, 2024, for EP Application No. 23 211 269.8, filed on Jun. 22, 2018, 5 pages. [cited by applicant]
Final Office Action mailed on Oct. 4, 2023, for U.S. Appl. No. 17/479,873, filed Sep. 20, 2021, 10 pages. [cited by applicant]
Final Office Action mailed on Jul. 8, 2024, for U.S. Appl. No. 17/479,873, filed Sep. 20, 2021, 11 pages. [cited by applicant]
Geets, X. et al. (Oct. 2007). “Adaptive biological image-guided IMRT with anatomic and functional imaging in pharyngo-laryngeal tumors: impact on target vol. delineation and dose distribution using helical tomotherapy,”… [cited by applicant]
Guohua, H. et al. (Nov. 2002). “Chapter 8: Radionuclide diagnosis and treatment,” in Bladder Tumor, Shanghai: Tongji University Press, first edition, first printing, p. 41 (with English Translation). [cited by applicant]
Hongsheng, S. (Aug. 2015). “Chapter 8: Nuclear medicine imaging,” in Practical Imaging Diagnosis, Xi'an Jiaotong University Press, first edition, first printing, p. 167 (with English Translation). [cited by applicant]
International Search Report mailed on Jun. 10, 2024, for PCT Patent Application No. PCT/US2024/017358, filed on Feb. 26, 2024, 4 pages. [cited by applicant]
Non-Final Office Action mailed on Mar. 5, 2024, for U.S. Appl. No. 17/479,873, filed Sep. 20, 2021, 11 pages. [cited by applicant]
Non-Final Office Action mailed on Jun. 24, 2024, for U.S. Appl. No. 18/295,448, filed Apr. 4, 2023, 8 pages. [cited by applicant]
Notice of Allowance mailed on Sep. 29, 2024, for U.S. Appl. No. 18/295,448, filed Apr. 4, 2023, 5 pages. [cited by applicant]
Notice of Allowance mailed on Jan. 15, 2025, for U.S. Appl. No. 17/479,873, filed Sep. 20, 2021, 9 pages. [cited by applicant]
Notice of Allowance mailed on Feb. 19, 2025, for U.S. Appl. No. 17/479,873, filed Sep. 20, 2021, 5 pages. [cited by applicant]
Peng, C. et al. (Jun. 2016). “Chapter 15: Clinical radiotherapy technique,” in Clinical Diagnosis and Treatment of Oncological Diseases, published by Jilin Science and Technology Press, first edition, first printing, p.… [cited by applicant]
Rocha, H. et al. (Jun. 20, 2011). “Influence of sampling in radiation therapy treatment design,” 18 [cited by applicant]
Shiying, Y. (Jul. 2009). “Chapter 4: Design of radiotherapy plan,” in Guidelines for Standardized Diagnosis and Treatment of Tumors, published by Huazhong University of Science and Technology Press, first edition, first… [cited by applicant]
Written Opinion of the International Searching Authority mailed on Jun. 10, 2024, for PCT Patent Application No. PCT/US2024/017358, filed on Feb. 26, 2024, 10 pages. [cited by applicant]
Xuening, Z. (Dec. 2010). “Chapter 2: Principles and Stereotactic Techniques of LEKSELL Gamma Knife,” in Gamma Knife Surgery for Intracranial Disease—Clinical Imaging, published by Tianjin Science and Technology Press, f… [cited by applicant]
Zhiliao, Z. et al. (Mar. 2002). “Progress in Physics of Tumor Radiotherapy,” Beijing Medical University and China Union Medical University Joint Publishing House, first edition, first printing, pp. 163-164 (with English… [cited by applicant]